Characteristics of the study subjects (N = 48)
| Characteristics . | n (%) . |
|---|---|
| Age, median (range), y | 58 (24-82) |
| Sex | |
| Male | 30 (62.5) |
| Female | 18 (37.5) |
| Ann Arbor stage | |
| I | 12 (26.1) |
| II | 11 (23.9) |
| III | 6 (13.0) |
| IV | 17 (37.0) |
| Missing | 2 |
| IPI score | |
| 0-1 | 15 (40.6) |
| 2 | 14 (37.8) |
| 3-5 | 8 (21.6) |
| Missing | 11 |
| Cell of origin | |
| GCB | 23 (67.6) |
| ABC | 11 (32.4) |
| Missing | 14 |
| LDH | |
| Elevated | 25 (53.2) |
| Not elevated | 22 (46.8) |
| Missing | 1 |
| Initial treatment | |
| R-CHOP | 32 (66.6) |
| EPOCH-R | 8 (16.7) |
| Other regimen | 8 (16.7) |
| Vital status, alive | 34 (70.8) |
| Characteristics . | n (%) . |
|---|---|
| Age, median (range), y | 58 (24-82) |
| Sex | |
| Male | 30 (62.5) |
| Female | 18 (37.5) |
| Ann Arbor stage | |
| I | 12 (26.1) |
| II | 11 (23.9) |
| III | 6 (13.0) |
| IV | 17 (37.0) |
| Missing | 2 |
| IPI score | |
| 0-1 | 15 (40.6) |
| 2 | 14 (37.8) |
| 3-5 | 8 (21.6) |
| Missing | 11 |
| Cell of origin | |
| GCB | 23 (67.6) |
| ABC | 11 (32.4) |
| Missing | 14 |
| LDH | |
| Elevated | 25 (53.2) |
| Not elevated | 22 (46.8) |
| Missing | 1 |
| Initial treatment | |
| R-CHOP | 32 (66.6) |
| EPOCH-R | 8 (16.7) |
| Other regimen | 8 (16.7) |
| Vital status, alive | 34 (70.8) |